Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Nanotherapeutics Awarded $20 Million NIAID/BARDA Contract to Develop Inhaled Gentamicin for Treatment of Aerosol Exposure to Bioterrorism Agents

Abstract:
Nanotherapeutics, Inc., today announced that it has been awarded a $20 Million 4-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA) to develop an inhaled version of the injectable drug, gentamicin, a broad-spectrum antibiotic that is used as a first-line therapy for pneumonic plague and tularemia, Category A bioterrorism agents. Both diseases are highly infectious and could pose a serious danger if used as an aerosolized biological weapon.

Nanotherapeutics Awarded $20 Million NIAID/BARDA Contract to Develop Inhaled Gentamicin for Treatment of Aerosol Exposure to Bioterrorism Agents

ALACHUA, FL | Posted on October 11th, 2007

Using its novel particle formulation, the company has developed NanoGENT™, an inhaled dry-powder formulation of gentamicin, to provide early treatment for exposure to biological warfare agents, as well as TB and other respiratory infections. In the event of an accidental or deliberate exposure to these agents, noninvasive drug delivery systems, such as improved inhaled and nasal delivery would be especially beneficial for administering wide-spread immediate post-exposure prophylaxis and treatment using disposable multi-dose inhalers with adequate shelf-life stability.

James D. Talton, Ph.D., President and C.E.O. of Nanotherapeutics and co-founder of the company said, "We are very pleased to receive this contract to fund this product development program. The continued support from the NIAID and BARDA of Nanotherapeutics' proprietary drug delivery systems is a terrific endorsement of our technologies and manufacturing capabilities. The continued development of NanoGENT™ with our partners Respirics, Next Breath, Lovelace Respiratory Research Institute, and i3Research is a strategically important milestone for the company as it demonstrates the utility of our technology to meet a significant medical need. We are confident we will be able to develop a novel improved formulation that can rapidly and effectively provide therapeutic results into a viable product."

Gentamicin, the front-line therapy for plague and tularemia, is a generic drug approved by the FDA for injection. For many years it has been used in a saline nebulized version to treat Pseudomonas respiratory infections, particularly in patients with cystic fibrosis. Nanotherapeutics and its collaborators will continue the clinical development of NanoGENT™ and expect to bring it to human clinical trials to evaluate the safety and pharmacokinetics in the fourth year of its NIAID/BARDA contract.

In 2005, Nanotherapeutics received funding from National Institute on Drug Abuse (NIDA) to develop an oral medication to treat opiate addiction. The company also received funding from the NIAID, as part of the NIH research program on Medical Countermeasures against Radiological and Nuclear Threats, to test the oral delivery of DTPA, an injectable treatment, and from Project Bioshield for preliminary testing of NanoGENT™. Nanotherapeutics has one approved injectable product and several products in advanced development, manufactured in-house under cGMP. This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Disease, National Institutes of Health (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA), Department of Health and Human Services (DHHS), under Contract No. HHSN27220070030C"

####

About Nanotherapeutics, Inc.
Nanotherapeutics Inc., an emerging specialty pharmaceutical company with expertise in the early stage development of pharmaceuticals, is a privately held corporation located in Florida. The company is a provider of specialized drug delivery systems that use the company’s discoveries in nanotechnology to develop novel drug therapies or improved formulations for existing therapies. The company employs several platform technologies to manipulate and enhance the properties of drugs. These technologies can be employed with new chemical entities or with generic drugs and can be used with the spectrum of existing drug types ranging from small synthetic molecules to large recombinant macromolecules.

Significant advances have been made in the area of nanometer-scale particle delivery, and Nanotherapeutics has created three proprietary drug delivery technologies: NanoQUAD™, NanoDRY™, and NanoCOAT™. These specialized proprietary techniques can improve the release rate and enhance both the rate and extent of drug uptake, thus increasing bioavailability. The consequences of these changes include more consistent drug therapy with potentially reduced dose and dose frequency requirements and fewer side effects.

For more information about Nanotherapeutics visit the company’s website at http://www.nanotherapeutics.com .

About Respirics

Respirics Inc. is a pulmonary drug delivery and development company located in Raleigh, North Carolina. The company is developing a line of branded inhalation drug products in its patented Acu-Breathe™ dry powder inhalers, and is working with pharmaceutical clients to enhance the delivery of their own compounds or formulations. Respirics combines proprietary inhalation technology with powder drug formulation expertise to develop unique drug delivery solutions. The company is committed to bringing effective, easy-to-use and affordable inhalation drug products to the patients who need them. For more information, visit www.respirics.com.

About Next Breath LLC

Located in Baltimore, MD, Next Breath is a contract services provider for pharmaceutical, biotech and medical device companies that bring new inhalation and nasal products to market. Next Breath has broad experience with drug delivery devices including nasal pumps, metered dose inhalers, dry power inhalers, nebulizers and spacers. Next Breath is a GMP laboratory providing an array of in vitro services ranging from pre-clinical formulation development to analytical testing, in support of submissions made to regulatory agencies. For more information, visit http://www.nextbreath.net .

About Lovelace Respiratory Research Institute

Lovelace Respiratory Research Institute (LRRI), through its wholly owned subsidiary, Lovelace Biomedical and Environmental Research Institute (LBERI), is a private biomedical research organization with a broad range of research capabilities and alliances with government, industry, universities, health advocacy organizations, and the public. LBERI offers this team its 50+ years of internationally recognized expertise in aerosol science and inhalation exposure technology, including aerosol generation and delivery techniques, sampling instrumentation and strategies, exposures, dosimetry of inhaled particles, and characterization and behavior of airborne particles, LBERI also provides safety, pharmacokinetic and toxicology support for products requiring FDA oversight. LBERI has a strong focus in virology, immunology, and infectious disease along with a complementary focus in the pharmaceutical and biopharmaceutical contract arena. LBERI supports national security, law enforcement, industry, and medical communities by improving the understanding of the possible use of biological weapons, biological agent pathogenesis, dissemination principles, and biothreat prevention.

About i3Research

i3 Research is a full-service, global contract research organization focused on: central nervous system; oncology; respiratory and infectious diseases, cardiology and endocrinology and metabolic disease. i3 Research is experienced in designing, planning and executing studies of all sizes and is driven by its therapeutic specialization; from project staffing and talent management to quality initiatives, such as six sigma, i3 Research relies on thought leaders in each of its therapeutic areas to integrate teams medically, scientifically and operationally, helping to ensure that customer needs are met or exceeded. i3 Research is a business unit of i3, a global Ingenix company, providing integrated scientific strategies and solutions throughout the pharmaceutical product lifecycle. Additional i3 business units are: i3 Drug Safety, engaged in pharmacovigilance and epidemiology; i3 Statprobe, a leader in comprehensive data services; i3 Pharma Resourcing, a world-class staffing partner; and i3 Innovus, delivering the science and solutions to achieve marketplace success. i3 helps companies gain sharper insights that lead to better patient care. For more information, visit http://www.i3global.com .

For more information, please click here

Contacts:
Nanotherapeutics
James D. Talton, Ph.D., 386-462-9663
President & CEO

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Govt.-Legislation/Regulation/Funding/Policy

University of Minnesota engineers make sound loud enough to bend light on a computer chip: Device could improve wireless communications systems November 28th, 2014

Single-atom gold catalysts may offer path to low-cost production of fuel and chemicals November 28th, 2014

Renishaw receives Queen's Award for spectroscopy developments November 25th, 2014

Vegetable oil ingredient key to destroying gastric disease bacteria: In mice, therapeutic nanoparticles dampen H. pylori bacteria and inflammation that lead to ulcers and gastric cancer November 25th, 2014

Nanomedicine

Production of Anticancer Drug from Nanofibers in Iran November 28th, 2014

Vegetable oil ingredient key to destroying gastric disease bacteria: In mice, therapeutic nanoparticles dampen H. pylori bacteria and inflammation that lead to ulcers and gastric cancer November 25th, 2014

Research reveals how our bodies keep unwelcome visitors out of cell nuclei November 24th, 2014

ASU, IBM move ultrafast, low-cost DNA sequencing technology a step closer to reality November 24th, 2014

Announcements

University of Minnesota engineers make sound loud enough to bend light on a computer chip: Device could improve wireless communications systems November 28th, 2014

Study details laser pulse effects on behavior of electrons November 28th, 2014

Single-atom gold catalysts may offer path to low-cost production of fuel and chemicals November 28th, 2014

Production of Anticancer Drug from Nanofibers in Iran November 28th, 2014

Homeland Security

Better bomb-sniffing technology: University of Utah engineers develop material for better detectors November 4th, 2014

Microrockets fueled by water neutralize chemical and biological warfare agents October 29th, 2014

NanoTechnology for Defense (NT4D) October 22nd, 2014

UT Arlington researchers develop transparent nanoscintillators for radiation detection for medical safety and homeland security September 29th, 2014

Military

University of Minnesota engineers make sound loud enough to bend light on a computer chip: Device could improve wireless communications systems November 28th, 2014

NRL Scientists Discover Novel Metamaterial Properties within Hexagonal Boron Nitride November 20th, 2014

Two sensors in one: Nanoparticles that enable both MRI and fluorescent imaging could monitor cancer, other diseases November 18th, 2014

Penn engineers efficiently 'mix' light at the nanoscale November 17th, 2014

New-Contracts/Sales/Customers

Iran Exports Nanodrugs to Syria November 24th, 2014

Tesla NanoCoatings Increasing Use of SouthWest NanoTechnologies Carbon Nanotubes (CNTs) for its Infrastructure Coatings and Paints: High Quality SMW™ Specialty Multi-wall Carbon Nanotubes Incorporated into Teslan®-brand coatings used by Transportation, Oil and Gas Companies November 19th, 2014

Artificial retina could someday help restore vision November 12th, 2014

Lomiko Signs Licensing Agreement to Produce and Supply Power Converter Systems to E-Commerce Customers October 29th, 2014

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More












ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE